medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 4

<< Back Next >>

Ann Hepatol 2014; 13 (4)

Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin

TMM de Kanter C, van Luin M, Solas C, Burger DM, Vrolijk JM

Language: English
References: 12
Page: 452-455
PDF size: 62.52 Kb.


ABSTRACT

A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected. The creatine kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline. The patient’s renal function remained unaffected. Fourteen days after hospitalization, creatine kinase level had returned to 230 IU/L and the patient was discharged. Telaprevir was considered the probable causative agent of an interaction with simvastatin according to the Drug Interaction Probability Scale. The interaction is due to inhibition of CYP3A4-mediated simvastatin clearance. Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood. In conclusion, with this case we illustrate that telaprevir as well as statins are susceptible to clinical relevant drug-drug interactions.


REFERENCES

  1. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.

  2. Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 2012; doi: 10.1016/j.jhep.2012.10.027. [Epub ahead of print]

  3. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 1620-8.

  4. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41: 674-80.

  5. FDA. Incivek: Prescribing information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm. (accessed 2013).

  6. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; 55: 4569-74.

  7. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33: 171-87.

  8. Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol 2010; 22: 644-50.

  9. Aarnoutse RE, Burger DM. When should we fear for statin interactions. In: Vissers, Kastelein, Stroes (eds.). Evidence- Based Management of Lipid Disorders. Chap. 17. Castle Hill Barns, UK: TFM Publishing limited; 2010.

  10. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 2009; 11: 272-8.

  11. http://www.hep-druginteractions.org/

  12. http://www.drugs.com/drug-interactions/telaprevir.html




2020     |     www.medigraphic.com